血清sCD44s及sCD44v6变化与乳腺癌的初步研究

目的:测定血清中sCD44s和sCD44v6含量并探讨其在乳腺癌中的临床意义。方法:用酶联免疫吸附试验(ELISA)检测38例乳腺癌患者及15例乳腺良性疾病患者和40例正常人血清中可溶性CD44s(sCD44s)和可溶性CD44v6(sCD44v6)的水平。结果:乳腺癌患者血清sCD44s和sCD44v6水平明显高于正常人和乳腺良性疾病患者(P＜0.01)。Ⅲ、Ⅳ期患者血清sCD44s和sCD44v6明显高于Ⅰ、Ⅱ期(P＜0.05);乳腺癌手术后1周sCD44v6明显低于手术前(P＜0.05),手术后2周sCD44v6更加明显(P＜0.01);手术后2周sCD44s明显低于手术前(P＜0.05)。结论:血清sCD44s和sCD44v6水平可作为诊断、治疗乳腺癌的辅助指标;乳腺癌血清中sCD44s和sCD44v6升高及降低与肿瘤负荷有关。

Serum sCD44s and sCD44v6 levels in breast cancer patients

AIM: To explore the clinical significance of detecting sCD44s and sCD44v6 in breast carcinoma. METHODS: Levels of serum soluble CD44 standard (sCD44s) and CD44 variant 6(sCD44v6) were detected by ELISA in 38 cases of breast cancer, 15 cases of benign breast diseases and 40 normal controls. RESULTS: The serum levels of sCD44s and sCD44v6 were significantly higher in patients with breast cancer than those with benign disease or normal controls. The serum concentrations of sCD44s and sCD44v6 in patients with stage Ⅲ, Ⅳ were significantly higher than those in patients with stageⅠ, Ⅱ(P＜0.01) .The level of sCD44v6 decreased markedly after one week operation and even more decreased after two weeks operation. The level of sCD44s was decreased significantly after two weeks operation. CONCLUSION: Serum levels of sCD44s and sCD44v6 may be a useful marker in the diagnosis and treatment of breast cancer. The changes in the levels of serum sCD44s and sCD44v6 may be the result of tumor burden, hence implicated in the prognosis of cancer patients.